Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician’s choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II)

Emma Connolly, Michelle White, Shankar Siva, Mathias Bressel, Adrienne See, Kate Hunter, Jennifer Tan, Vanessa Panettieri, Daphne Day, Keelan Byrne, Amelia McCartney, Kate Webber, Katrina Woodford, Steven David

Open source

DOI: 10.1136/bmjopen-2026-119811
Published: 2026-09
Container: BMJ Open
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2026-119811,
  title = {Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician’s choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II)},
  author = {Emma Connolly and Michelle White and Shankar Siva and Mathias Bressel and Adrienne See and Kate Hunter and Jennifer Tan and Vanessa Panettieri and Daphne Day and Keelan Byrne and Amelia McCartney and Kate Webber and Katrina Woodford and Steven David},
  year = {2026},
  journal = {BMJ Open},
  doi = {10.1136/bmjopen-2026-119811},
  url = {https://doi.org/10.1136/bmjopen-2026-119811}
}

RIS

TY  - JOUR
TI  - Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician’s choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II)
AU  - Emma Connolly
AU  - Michelle White
AU  - Shankar Siva
AU  - Mathias Bressel
AU  - Adrienne See
AU  - Kate Hunter
AU  - Jennifer Tan
AU  - Vanessa Panettieri
AU  - Daphne Day
AU  - Keelan Byrne
AU  - Amelia McCartney
AU  - Kate Webber
AU  - Katrina Woodford
AU  - Steven David
PY  - 2026
JO  - BMJ Open
DO  - 10.1136/bmjopen-2026-119811
UR  - https://doi.org/10.1136/bmjopen-2026-119811
ER  -

APA

Connolly, E., White, M., Siva, S., Bressel, M., See, A., Hunter, K., Tan, J., Panettieri, V., Day, D., Byrne, K., McCartney, A., Webber, K., Woodford, K., & David, S. (2026). Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician’s choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II). BMJ Open. https://doi.org/10.1136/bmjopen-2026-119811

Source records

crossref · retrieved 2026-09-25T19:31:00.343Z